Monitoring Interferon Gamma Production in Adults in Intensive Care After Severe Trauma, High-Risk Surgery, or Acute Respiratory Distress

What this Trial Is About

Researchers are studying the immune response in patients admitted to intensive care after severe trauma, high-risk surgery, or acute respiratory distress syndrome. These patients often experience an initial strong inflammation followed by an immune suppression phase, which increases the risk of infections and complications. The study aims to monitor interferon gamma IFN-b3 production as a marker of immune function to better understand immune status changes in these critically ill patients. The study involves collecting blood samples daily from day 1 to day 7, then every 72 hours until the patient is discharged from intensive care or up to day 28. Blood will be taken using an arterial catheter already in place, and no extra procedures are required beyond routine care. This observational study will analyze IFN-b3 production and other immune markers such as mHLA-DR expression to characterize immune function over time. Participants will be monitored closely during their intensive care stay with regular blood tests to measure immune responses. Researchers will also collect data on infections, viral reactivations, mechanical ventilation duration, septic shock, renal impairment, and length of ICU stay. The main outcome measured is IFN-b3 production daily and then every 72 hours, with monitoring continuing up to 28 days or until ICU discharge.

Kinetics of INF-γ Production in Intensive Care Patients